More Impact AG / DE000A1PG979

Frankfurt, April 9, 2025 – More Impact AG (ISIN: DE000A1PG979, "More Impact"), a listed high-tech medical hub, and its wholly owned subsidiary BG Braingate Technology GmbH ("Braingate") are launching the Z-Boxx. Braingate is thus integrating its patented inhaler technology into a marketable product. The Z-Boxx allows smokers to gradually quit nicotine without having to give up the smoking experience. The Z-Boxx thus makes an active contribution to improving health and also significantly reduces the burden on the environment by avoiding waste. The comprehensive market launch of the innovative product is planned for the fourth quarter of 2025.  The Z-Boxx is based on an innovative, patented filter and vaporization technology that heats tobacco instead of burning it. The actual nicotine dosage can be regulated so that the Z-Boxx can be used to continuously reduce the smoker's nicotine intake - right up to complete nicotine abstinence. In addition, no typical combustion products such as tar or carbon monoxide are produced. The mechanism of action of the Z-Boxx therefore directly addresses the most harmful aspects of smoking. Nevertheless, the smoking experience remains authentic in taste. Compared to disposable e-cigarettes or traditional tobacco products, the Z-Boxx produces no environmentally harmful filter waste, as filterless cigarettes are used and harmful substances are filtered out. According to the WHO, an estimated 4.5 trillion cigarette filters end up in the environment worldwide every year. The battery of the Z-Boxx can also be flexibly removed and recharged, which significantly reduces electronic waste. Dr. Karsten Behlke, Managing Director of the subsidiary BG Braingate Technology GmbH: “The Z-Boxx combines the traditional smoking experience with effective nicotine cessation. Thanks to the patented technology, the device specifically filters out harmful and polluting substances. The Z-Boxx thus paves the way for a healthier lifestyle in society.” About More Impact AG
More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model. Contact – Investor & Media Relations
edicto GmbH
Axel Mühlhaus / Svenja Liebig
+49 69 90550 5-50
moreimpact@edicto.de